1. Home
  2. NTLA vs HIPO Comparison

NTLA vs HIPO Comparison

Compare NTLA & HIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • HIPO
  • Stock Information
  • Founded
  • NTLA 2014
  • HIPO 2015
  • Country
  • NTLA United States
  • HIPO United States
  • Employees
  • NTLA N/A
  • HIPO N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • HIPO Property-Casualty Insurers
  • Sector
  • NTLA Health Care
  • HIPO Finance
  • Exchange
  • NTLA Nasdaq
  • HIPO Nasdaq
  • Market Cap
  • NTLA 931.3M
  • HIPO 923.0M
  • IPO Year
  • NTLA 2016
  • HIPO N/A
  • Fundamental
  • Price
  • NTLA $9.02
  • HIPO $32.61
  • Analyst Decision
  • NTLA Buy
  • HIPO Strong Buy
  • Analyst Count
  • NTLA 22
  • HIPO 5
  • Target Price
  • NTLA $19.83
  • HIPO $35.40
  • AVG Volume (30 Days)
  • NTLA 8.3M
  • HIPO 299.3K
  • Earning Date
  • NTLA 11-06-2025
  • HIPO 11-05-2025
  • Dividend Yield
  • NTLA N/A
  • HIPO N/A
  • EPS Growth
  • NTLA N/A
  • HIPO N/A
  • EPS
  • NTLA N/A
  • HIPO 3.71
  • Revenue
  • NTLA $57,528,000.00
  • HIPO $450,000,000.00
  • Revenue This Year
  • NTLA $8.51
  • HIPO $27.93
  • Revenue Next Year
  • NTLA N/A
  • HIPO $22.04
  • P/E Ratio
  • NTLA N/A
  • HIPO $8.83
  • Revenue Growth
  • NTLA 33.52
  • HIPO 34.41
  • 52 Week Low
  • NTLA $5.90
  • HIPO $19.92
  • 52 Week High
  • NTLA $28.25
  • HIPO $38.98
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 35.68
  • HIPO 44.73
  • Support Level
  • NTLA $8.96
  • HIPO $32.46
  • Resistance Level
  • NTLA $8.88
  • HIPO $33.63
  • Average True Range (ATR)
  • NTLA 0.63
  • HIPO 1.52
  • MACD
  • NTLA 0.26
  • HIPO 0.01
  • Stochastic Oscillator
  • NTLA 38.33
  • HIPO 42.83

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About HIPO Hippo Holdings Inc.

Hippo Holdings Inc is a home insurance group that created a new standard of care and protection for homeowners. It provides insurance for computers, home offices, electronics, appliances, water backup, and service line coverage, among others. It has three reportable segments Services segment earns fees and commission income without assuming underwriting risk or need for reinsurance, Insurance-as-a-Service managed through the company's subsidiary Spinnaker is a platform to support third-party MGAs, and the Hippo Home Insurance Program engaged in homeowners insurance business. It generates the majority of its revenue from the Insurance-as-a-Service segment.

Share on Social Networks: